ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Atypical Antipsychotic — Multimodal (Schizophrenia / Bipolar Depression) Pregnancy: Avoid — insufficient human data. Risk of extrapyramidal symptoms and withdrawal in neonates if used in third trimester (class effect of antipsychotics).

Lumateperone

Brand names: Caplyta

Adult dose

Dose: 42 mg once daily in the evening
Route: Oral
Frequency: Once daily (evening — take with food)
Max: 42 mg/day
Schizophrenia (adults) and bipolar depression (bipolar I or II, as monotherapy or adjunct to lithium or valproate). Must be taken in the evening with food — food increases absorption 9-fold (major food effect). Source: BNF 90; MHRA conditional approval; ITI-007 clinical programme.

Paediatric dose

Dose: Not licensed under 18 years N/A/kg
Route: N/A
Frequency: N/A
Max: N/A
Not licensed in paediatric schizophrenia or bipolar disorder.

Dose adjustments

Renal

No dose adjustment required for renal impairment.

Hepatic

Moderate hepatic impairment (Child-Pugh B): reduce dose to 21 mg once daily. Severe (Child-Pugh C): avoid — insufficient data, significantly increased exposure.

Paediatric weight-based calculator

Not licensed in paediatric schizophrenia or bipolar disorder.

Clinical pearls

  • Multimodal mechanism — beyond D2 blockade: lumateperone simultaneously acts as a D2 receptor pre-synaptic agonist (reduces dopamine excess, antipsychotic effect), post-synaptic partial agonist at low receptor occupancy, serotonin reuptake inhibitor (SSRI-like antidepressant component), and 5-HT2A antagonist. This multimodal profile explains its antipsychotic AND antidepressant efficacy — particularly relevant for bipolar depression where depression is the dominant burden.
  • Low metabolic burden — clinically significant: many atypical antipsychotics (olanzapine, quetiapine, clozapine) cause significant weight gain and metabolic syndrome over months. Lumateperone's low H1 antihistamine and low 5-HT2C activity result in minimal weight gain in trials. Important for long-term adherence in schizophrenia and bipolar disorder where metabolic health is already compromised.
  • CAPLYTA bipolar depression trial (Calabrese et al. NEJM 2021): lumateperone 42 mg significantly reduced MADRS score vs placebo in bipolar I and II depression — both as monotherapy and as adjunct to lithium/valproate. Effect size comparable to quetiapine but with less sedation and weight gain.
  • Food effect — critical counselling point: taking lumateperone without food reduces absorption by 90% (10-fold difference). Always take in the evening WITH food. This is one of the most significant food effects for any psychiatric drug — non-adherence to the food instruction = near-zero drug effect.
  • Low EPS advantage: D2 receptor occupancy at therapeutic doses is lower than typical antipsychotics (~40% vs 65–80% for risperidone/haloperidol). This translates to less akathisia, parkinsonism, and tardive dyskinesia risk — important for long-term use. Source: BNF 90; Calabrese et al. NEJM 2021; Davis et al. JAMA Psychiatry 2019 (schizophrenia); MHRA SPC Caplyta.

Contraindications

  • Strong CYP3A4 inducers (rifampicin, carbamazepine) — concurrent use contraindicated
  • Strong CYP3A4 inhibitors: dose adjustment required
  • Moderate or severe hepatic impairment (reduce dose)
  • Known hypersensitivity to lumateperone

Side effects

  • Somnolence, fatigue (most common — take in evening specifically to mitigate this)
  • Dry mouth, nausea
  • Minimal weight gain (key advantage over many atypicals — clinically important for metabolic monitoring)
  • Minimal extrapyramidal side effects (low D2 occupancy at therapeutic doses)
  • Minimal QTc prolongation (unlike many antipsychotics)
  • Minimal metabolic syndrome (low prolactin elevation, low glucose/lipid effects)

Interactions

  • Strong CYP3A4 inhibitors (clarithromycin, itraconazole, ketoconazole): increase lumateperone — reduce to 21 mg daily
  • Strong CYP3A4 inducers (rifampicin, St John's Wort): markedly reduce lumateperone — contraindicated
  • UGT inhibitors (valproate): may increase lumateperone exposure — monitor for enhanced side effects; valproate is used intentionally as combination partner in bipolar depression
  • CNS depressants: additive sedation

Monitoring

  • Weight and BMI at baseline, 4 weeks, 12 weeks, then every 6 months
  • Fasting glucose and lipid profile at baseline and 3–6 monthly
  • Blood pressure at each visit (orthostatic hypotension)
  • Mental state examination and depression/psychosis rating scales
  • Extrapyramidal symptoms (low risk but monitor)
  • Liver function tests at baseline (hepatic dose adjustment required)

Reference: BNFc; BNF 90; Davis et al. JAMA Psychiatry 2019 (schizophrenia trial); Calabrese et al. NEJM 2021 (bipolar depression); MHRA SPC Caplyta. Verify against your local formulary and the latest BNF before prescribing.

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways